Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Conditions are right for biopharma M&A to break out

<< Previous

Bullboard Posts

Next >>

Comment by Capitalistaon May 16, 2023 9:47am

126 Views

Post# 35450038

RE:RE:RE:RE:RE:RE:Conditions are right for biopharma M&A to break out

Agreed, fox7mf. I doubt that we'll see anything more than a several-day-long rise/fall with ASCO (much as I would like to see something more permanent). ONC will not see a sustained price rise until some sort of business deal is announced. Study results have not moved share price significantly in the last year or two. We need a business deal.

<< Previous

Bullboard Posts

Next >>

Changing Europe’s dependency on HREE from China